큐라티스

348080KOSDAQ자연과학 및 공학 연구개발업

52.5 / 100

Reference Date: 2026-06-10

Financial Score28.0 / 40

News Sentiment12.5 / 25

Momentum2.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Plunged 39.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Curatis develops vaccines using its platform technology, including QTP101 (tuberculosis prevention), QTP105 (schistosomiasis prevention), and QTP104 (next-generation mRNA-based COVID-19 vaccine). QTP101 has received global Phase 2b/3 trial approval, and the company also provides CMO/CDMO services and open innovation solutions for drug development.

Number of Employees

47people

Average Salary

58.4M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 62.704.0Point

PBR

1.21Industry Average 3.247.0Point

Half of industry avg (excellent)

ROE

-91.68Industry Average -32.093.5Point

2.9x industry avg (excellent)

Debt Ratio

0.06Industry Average 7.318.0Point

Half of industry avg (excellent)

Trend 2023~20255.5 / 10 points

Revenue Growth Rate

3.0 / 3

Avg ▲246.8% (2-year basis)

Operating Profit Growth Rate

2.5 / 3

Avg ▲15.6% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -92.3% (improving, 2yr)

Detailed News Sentiment

1 totalPositive 0Neutral 1Negative 0Average Sentiment Score 50

Neutral
큐라티스, 6월1일 임시주총 개최...결손 보전 무상감자 안건
큐라티스는 임시주주총회를 통해 자본구조 개선을 위한 무상감자를 논의하지만, 직접적인 시장 영향은 제한적이다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 464Won52-week high 1,41552-week low 464

1-month return0.0Point

1m -39.11% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

3 totalPositive 0Neutral 3Negative 0

Neutral임시주주총회결과2026-06-01
Neutral주주총회소집공고2026-05-15
Neutral분기보고서 (2026.03)2026-05-14